Page 5 - Diagnostics

Diagnostic industry may log 55% revenue growth in FY22, says report

The report by Icra Ratings also expects the prices of diagnostic tests to stabilise at current levels due to focus on volume growth and higher competitive intensity from unorganized players

We entered an otherwise hard market with Suburban deal: Dr Lal Pathlabs MD

In a Q&A, Om Manchanda says the firm is now growing organically in the Southern market, but is open to inorganic opportunities there

Lupin forays into diagnostics business; launch expected next month

Also, Lupin is looking for franchise partners with an investment of Rs 2-5 lakh without any security deposit

Sterling Accuris to raise Rs 250 crore from fund managed by Morgan Stanley

Diagnostic lab chain Sterling Accuris Wellness on Monday said it has inked a pact to raise Rs 250 crore from a fund managed by Morgan Stanley Pvt Equity Asia in order to expand operations. Sterling, which started operations in 2016, has over 1,000 employees and operates around 150 labs and collection centers in Gujarat, Delhi, Rajasthan and Madhya Pradesh. The company is aiming a revenue of around Rs 250 crore in the current fiscal year. As diseases become more complex, the need for their quick and accurate diagnosis through testing will become more critical," Sterling Accuris Chairman Girish Patel said in a statement. This will lead to increased customer preference towards organised pathology lab networks, he added. "Over the last five years, Sterling Accuris have built a strong business in the markets we operate in and the growth capital infusion from a seasoned investor like Morgan Stanley will help the team accelerate the execution of our expansion plan," Patel noted. During

Molbio Diagnostics developing more tests for Truenat platform

Molbio is preparing test kits for zika, cholera, nipah, sickle cell anaemia, ch­olera, influenza, mumps, syp­hillis, yellow fever, HIV2 etc

Fortis posts Q1 profit of Rs 430 cr on revenue growth, exceptional gain

Revenue grows 132% in Q1FY22, with that from diagnostics putting up the best show

Thyrocare, Lal Pathlabs: Diagnostic stocks trade weak. Should you worry?

Given the weakness seen on Monday, should you be worried regarding stocks from this sector? Here is how they look on the charts

Neuberg Diagnostics to expand in Africa, ME & India, invest Rs 150cr

Diagnostics major Neuberg Diagnostics plans to expand its international as well as domestic presence with an investment of Rs 150 crore, said a top company official

Exploring windows to enhance shareholder value: Thyrocare Technologies

Thyrocare's market capitalisation is around Rs 6,916 crore. The deal thus could be for a shareholding in the firm

Neuberg Diagnostics says will cross Rs 1,000 cr revenue milestone in FY22

The company is planning to set up 10 more labs in the northern and eastern parts of the country for deeper penetration

Indian researchers develop AI that may help in the fight against Covid-19

Given limited testing facilities for Covid-19, there's a rush to develop AI tools for quick analysis using X-rays. Experts say it can be very useful in smaller towns where access to CT scans is poor

Stocks of diagnostic chains factoring in near-term positives: Analysts

They say it will be a good strategy to exit these stocks at least for now. Over the long-run, however, Dr Lal Pathlabs, Metropolis Healthcare and Thyrocare Tech still offer room for growth

Bet on these diagnostic stocks for up to 19% return as Covid-19 cases flare

According to the Union Health Ministry data, India recorded 1,03,558 coronavirus infections on Sunday, pushing the nationwide Covid tally to 1.25 crore

Peepul Capital-owned Medall Diagnostics plans to go for an IPO in 4 years

Medall's revenue, approximately Rs 400 crore at present, is estimated to increase to Rs 1,000 crore in three to four years

Testing recovery gains factored in Thyrocare Technologies stock

Margin pressures and valuations would limit major upsides

Street signs: Debt funds under pressure, diagnostic firms go weak and more

Buying shares of companies that operate in the cold storage space is emerging as a hot theme on Dalal Street

Dr Lal PathLabs, Metropolis: Here's how healthcare stocks look on charts

Thyrocare Technologies has the strong support of 50-DMA, currently placed at Rs 988 levels.

Diagnostics players post healthy returns on quick rebound in business

Sharp rise in non-Covid business and strong revenue growth indicated by Thyrocare, Metropolis prop up sentiment

Thyrocare, Dr Lal PathLabs: Healthcare stocks can rally more, charts show

A new all time high shows bullish sentiment is here to stay in these stocks.

Diagnostic labs pin hopes on Covid-19 test bouquets to revive revenues

Non-Covid revenues are back to 80% of Jan levels. Some expect demand to be 1.2 times pre-Covid level by Diwali